The diagnostic yield of malignant lymphoma by convex-probe endobronchial ultrasound bronchoscope: a multicenter prospective observational study

The diagnostic yield of malignant lymphoma by convex-probe endobronchial ultrasound bronchoscope: a multicenter prospective observational study - The diagnostic yield of malignant lymphoma by convex-probe endobronchial ultrasound bronchoscope: a multicenter prospective observational study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060892

Enrollment

Registered

2026-03-11

Start date

2026-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with hilar/mediastinal lesions and/or lymph nodes, where malignant lymphoma lesions are considered. 2. 18 years or older 3. Informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who are already diagnosed malignant lymphoma pathologically by other lesions.

Design outcomes

Primary

Measure	Time frame
Calculation of diagnostic yields for each method with endobronchial ultrasound bronchoscope for hilar and mediastinal lesions and hilar and mediastinal lymph node.	—

Secondary

Measure	Time frame
1. Evaluation of diagnostic yields by biopsy devises 2. Evaluation of adverse events associated with biopsies 3. Evaluation of the relationship between diagnostic yields and flow cytometry 4. Evaluation of the relationship between diagnostic yields and rapid on-site cytological evaluation (ROSE) 5. Evaluation of the relationship between diagnostic yields and the number of biopsies and tissue specimens 6. Evaluation of the relationship between target lesion sizes and diagnostic yields 7. Evaluation of diagnostic yields for EBUS-TBNA alone versus EBUS-TBNA preceded by EBUS-IFB/MFB or EBUS-TMC 8. Evaluation of diagnostic yields for EBUS-TBNA alone versus the combined diagnostic yields of EBUS-TBNA with EBUS-IFB/MFB and EBUS-TMC	—

Measure

Time frame

1. Evaluation of diagnostic yields by biopsy devises 2. Evaluation of adverse events associated with biopsies 3. Evaluation of the relationship between diagnostic yields and flow cytometry 4. Evaluation of the relationship between diagnostic yields and rapid on-site cytological evaluation (ROSE) 5. Evaluation of the relationship between diagnostic yields and the number of biopsies and tissue specimens 6. Evaluation of the relationship between target lesion sizes and diagnostic yields 7. Evaluation of diagnostic yields for EBUS-TBNA alone versus EBUS-TBNA preceded by EBUS-IFB/MFB or EBUS-TMC 8. Evaluation of diagnostic yields for EBUS-TBNA alone versus the combined diagnostic yields of EBUS-TBNA with EBUS-IFB/MFB and EBUS-TMC

—

Countries

Japan

Contacts

Public ContactAtsushi Torii

NHO Nagoya Medical Center Department of Respiratory Medicine

a51009068@gmail.com052-951-1111

Outcome results